The Natural Stilbenoid (–)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants-Reference-Cited by-同舟云学术

The Natural Stilbenoid (–)-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants

Published:2021-11-17 Issue:12 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Tietjen Ian¹^ORCID,Cassel Joel¹,Register Emery T.¹,Zhou Xiang Yang¹,Messick Troy E.¹,Keeney Frederick¹,Lu Lily D.¹,Beattie Karren D.²,Rali Topul³,Tebas Pablo⁴,Ertl Hildegund C. J.¹,Salvino Joseph M.¹,Davis Rohan A.²,Montaner Luis J.¹

Affiliation:

1. The Wistar Institute, Philadelphia, Pennsylvania, USA

2. Griffith Institute for Drug Discovery, School of Environment and Science, Griffith University, Brisbane, QLD, Australia

3. School of Natural and Physical Sciences, The University of Papua New Guinea, Port Moresby, Papua New Guinea

4. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA

Abstract

Antivirals are urgently needed to combat the global SARS-CoV-2/COVID-19 pandemic, supplement existing vaccine efforts, and target emerging SARS-CoV-2 variants of concern. Small molecules that interfere with binding of the viral spike receptor binding domain (RBD) to the host angiotensin-converting enzyme II (ACE2) receptor may be effective inhibitors of SARS-CoV-2 cell entry.

Funder

Wistar Science Discovery Fund

Simon Fraser University - Griffith University Collaborative Grant

Australian Research Council

Robert I Jacobs Fund of the Philadelphia Foundation

Herbert Kean, MD Family Professorship

Department of Health | National Health and Medical Research Council

Gouvernement du Canada | Canadian Institutes of Health Research

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology